Boston Therapeutics is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and Ipoxyn™ for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation.

The company’s lead product, PAZ320, is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics has developed the PAZ320 drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels.

Ipoxyn™ is an injectable prescription drug developed to prevent necrosis and treatment of ischemic conditions which may lead to necrosis, a form of cell injury resulting in the death of cells in living tissue, such as with gangrene. The gloco-protein-based therapeutic agent is applicable to both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

OxyFex™ is the company’s veterinary facsimile to Ipoxyn™, designed for the veterinary market as blood replacement and oxygen delivery to damaged or ischemic tissue due to trauma, surgery anemia, and other disease conditions.

Boston Therapeutics’ strategy is to develop PAZ320 and Ipoxyn™ by using the U.S. Food and Drug Administration’s Prescription Drug User Fee Act (PDUFA), which provides an expedited means of drug development.

Moving forward, the company continues to build on its momentum from positive results for PAZ320’s phase 2a safety and efficacy trial, and recently raised $5.3 million to fund ongoing clinical trials for PAZ320. Boston Therapeutics in early November began enrolling patients in a phase IIb clinical study on PAZ320.

For more information, visit: www.bostonti.com

Let us hear your thoughts below: